Researchers introduce novel model of acquired oxaliplatin resistance in a sub-line of non-MYCN-amplified neuroblastoma cell line that was adapted to growth in the presence of 4000 ng/mL oxaliplatin (SK-N-ASrOXALI⁴⁰⁰⁰), as well as cisplatin and carboplatin.

See the source article by following the link below:
Researchers introduce novel model of acquired oxaliplatin resistance in a sub-line of non-MYCN-amplified neuroblastoma cell line that was adapted to growth in the presence of 4000 ng/mL oxaliplatin (SK-N-ASrOXALI⁴⁰⁰⁰), as well as cisplatin and carboplatin.